

Hybrid PHC 2024 Institut Pasteur - Paris 18 - 19 March



MONDAY, MARCH 18TH Scientific program



| 08:00 08:30 | Registration and Welcome coffee Visit of the exhibition and posters area |
|----------------|--|
| 08:30 | Introduction Patrick MARCELLIN (France), Laurent CASTERA (France) |
| 08:40 10:00 | HEPATITIS B - OPTIMAL MANAGEMENT Chairs: Rafael ESTEBAN (Spain), Jidong JIA (China) |
| 08:40 | Long term efficacy and safety of NUCs: follow-up studies of TDF and TAF Maria BUTI (Spain) |
| 08:55 | Effects of NUC therapy on the incidence of HCC Seng Gee LIM (Singapore) |
| 09:10 | Controversy: treat everyone with detectable HBV DNA? Yes ~ Jidong JIA (China) No ~ Thomas BERG (Germany) Discussion |
| 09:40 | New antivirals and new therapeutic strategies Fabien ZOULIM (France) |
| 10:00 10:30 | Coffee break Visit of the exhibition and posters area |
| 10:30 10:50 | STATE OF THE ART LECTURE Advances in the management of alcohol-related liver disease |
| | Aleksander KRAG (Denmark) |
| 10:50 12:10 | HEPATITIS DELTA - OPTIMAL TREATMENT Chairs: Mario RIZZETTO (Italy), Kosh AGARWAL (UK) |
| 10:50 | The EASL guidelines on hepatitis delta Tarik ASSELAH (France) |
| 11:05 | Is chronic hepatitis delta more severe than chronic hepatitis B? Raymundo PARANA (Brazil) |
| 11:20 | PEG-IFN monotherapy Georgios PAPATHEODORIDIS (Greece) |
| 11:35 | Do NUCs improve the efficacy of Bulevirtide? Vasily ISAKOV (Russia) |
| 11:50 | Controversy: bulevirtide - Combine or not to PEG IFN? Yes ~ Heiner WEDEMEYER (Germany) No ~ Pietro LAMPERTICO (Italy) Discussion |
| 12:10 12:30 | STATE OF THE ART LECTURE What's new in auto-immune liver diseases? |
| | Michael MANNS (Germany) |
| 12:30 12:45 | Break Lunch boxes distribution in the exhibition |

MONDAY, MARCH 18TH





| 12:45 13:45 | SYMPOSIUM ~ CIS Auditorium Partr & WORKSHOP ~ Congress center, Room 1 | ners' sessions program |
|----------------|--|------------------------|
| 13:45 14:00 | Coffee break Visit of the exhibition and posters area | |
| 14:00 14:45 | R&D SESSION 1 Partr The drug pipelines presented by Companies | ners' sessions program |
| 14:45 15:40 | HEPATITIS C: ARE WE ON TIME? Chairs: Robert FLISIAK (Poland), Ana Carolina FERREIRA NETTO CARDOSO (Brazil) | |
| 14:45 | What actions to take to achieve HCV elimination? Robert GISH (USA) | |
| 15:00 | Improving HCV-related morbidity and mortality Robert FLISIAK (Poland) | |
| 15:15 | Improving immune-related extrahepatic manifestations Patrice CACOUB (France) | |
| 15:30 | Discussion | |
| 15:40 16:10 | Coffee break Visit of the exhibition and posters area | |
| 16:10 17:20 | ADVANCES IN THE MANAGEMENT OF END-STAGE LIVER DISEASE Chairs: Shiv SARIN (India), Richard MOREAU (France) | |
| 16:10 | ICU admission of patients with cirrhosis: indications, futility Francois DURAND (France) | |
| 16:25 | New insights into decompensated cirrhosis: the ACLARA study Adrian GADANO (Argentina) | |
| 16:40 | Encephalopathy revisited Dominique THABUT (France) | |
| 16:55 | Sarcopenia, frailty in end-stage liver disease Claire FRANCOZ (France) | |
| 17:10 | Discussion | |
| 17:20 17:50 | AWARD 2024 Chair: Patrick MARCELLIN (France) | |
| 17:20 | Vascular liver diseases Dominique VALLA (France) | |
| 17:50 18:00 | POSTER PRIZE Chair: Patrick MARCELLIN (France) | |

MONDAY, MARCH 18TH Scientific program



| 18:00 18:20 | TAKE HOME MESSAGES Marc BOURLIÈRE (France) | |
|----------------|---|----------------------------|
| 18:20 | Conclusion Patrick MARCELLIN (France), Laurent CASTERA (France) | |
| 18:30 19:00 | SYMPOSIUM ~ CIS Auditorium | Partners' sessions program |
| 19:00 | End of the 1st day | |

TUESDAY MARCH 19TH

Scientific program



| 08:00 08:30 | Registration and Welcome coffee Visit of the exhibition and posters area |
|----------------|---|
| 08:30 | Introduction Patrick MARCELLIN (France), Laurent CASTERA (France) |
| 08:40 | MASLD AND TYPE 2 DIABETES (T2D) |
| 09:40 | Chairs: Jeffrey LAZARUS (Spain), Jörn SCHATTENBERG (Germany) |
| 08:40 | Pathophysiological relationship between MASLD and T2D Amalia GASTALDELLI (Italy) |
| 08:55 | High prevalence of severe liver lesions in T2D: lessons from QUID-NASH Laurent CASTERA (France) |
| 09:10 | Impact of MASH on T2D treatment and management Michael RODEN (Germany) |
| 09:25 | Discussion |
| 09:40 10:00 | STATE-OF-THE ART LECTURE Update on the global epidemiology of MASLD and MASH |
| | Zobair YOUNOSSI (USA) |
| 10:00 10:30 | Coffee break Visit of the exhibition and posters area |
| 10:30 11:30 | NON-INVASIVE TESTS (NITS) IN MASLD IN 2024 Chairs: Lawrence SERFATY (France), Massimo PINZANI (UK) |
| 10:30 | Limitations and challenges in the use of NITs Emmanouil TSOCHATZIS (UK) |
| 10:45 | Prognostic value of NITs Mazen NOUREDDIN (USA) |
| 11:00 | NITs use in clinical practice Jérôme BOURSIER (France) |
| 11:15 | Discussion |
| 11:30 | TREATING MASH IN 2024 |
| 12:30 | Chairs: Laurent CASTERA (France), Arun SANYAL (USA) |
| 11:30 | Benefit of weight loss in MASH Raluca PAÏS (France) |
| 11:45 | Clinical trial landscape in MASH Stephen HARRISON (USA) |
| 12:00 | Treatment response in MASH: are we ready for NITs? Arun SANYAL (USA) |
| 12:15 | Discussion |
| 12:30 12:45 | Break Lunch boxes distribution in the exhibition |

TUESDAY MARCH 19TH

Scientific program



| 12:45 13:45 | SYMPOSIUM ~ CIS Auditorium Partners' sessions program & WORKSHOP ~ Congress center, Room 1 |
|----------------|--|
| 13:45 14:00 | Coffee break Visit of the exhibition and posters area |
| 14:00 14:45 | R&D SESSION 2 Partners' sessions program The drug pipelines presented by Companies |
| 14:45 15:40 | HCC SESSION 1: DIAGNOSIS AND STAGING Chairs: Massimo COLOMBO (Italy), Pierre NAHON (France) |
| 14:45 | Risk stratification-based surveillance of HCC Peter JEPSEN (Denmark) |
| 15:00 | Toward multiscale imaging of HCC Valérie PARADIS, Maxime RONOT (France) |
| 15:30 | Discussion |
| 15:40 16:00 | STATE OF THE ART LECTURE Management of invasive procedures in patients with cirrhosis |
| | Pierre-Emmanuel RAUTOU (France) |
| 16:00 16:30 | Coffee break Visit of the exhibition and posters area |
| 16:30 17:30 | HCC SESSION 2: MANAGEMENT Chair: Norah TERRAULT (USA), Massimo COLOMBO (Italy) |
| 16:30 | Interventional radiology Laura CROCETTI (Italy) |
| 16:45 | Towards manipulation of responses to immunotherapy in HCC Josep M. LLOVET (Spain) |
| 17:00 | Expanding liver transplantation options Norah TERRAULT (USA) |
| 17:15 | Discussion |
| 17:30 17:50 | TAKE HOME MESSAGES Michael FRIED (USA) |
| 17:50 | Conclusion Patrick MARCELLIN (France), Laurent CASTERA (France) |
| 18:00 | End of the congress |

MONDAY, MARCH 18TH Partners' sessions program



| | | OIC Auditorium |
|--------------------|--|-------------------------|
| 12:45 13:45 | WORKSHOP ABBVIE Unlocking the promise of artificial intelligence to achieve HCV elimination | cis Auditorium abbvie |
| | Chair: Markus CORNBERG (Hannover, Germany) | |
| 12:45 | Communication 1 Juan TURNES (Vigo, Spain) | |
| 13:15 | Communication 2 Mike BOYADJIAN (Abbvie, USA) | |
| | | Congress center, Room 1 |
| 12:45 13:45 | WORKSHOP ~ supported by an unrestricted grant from CYMABAY Emerging therapies in the management of people living with PBC | CYMABAY |
| | Chairs: Gideon HIRSCHFIELD (Toronto, Canada), Stephen HARRISON (San Antonio, U | SA) |
| 12:45 | PPARs: an emerging therapeutic option for people living with PBC Gideon HIRSCHFIELD (Toronto, Canada), Stephen HARRISON (San Antonio, USA) | |
| 12:50 | Redefining the treatment landscape in PBC: target potency, safety and normality Gideon HIRSCHFIELD (Toronto, Canada) | |
| 13:05 | Phase 3 Trials Primary and Key Secondary Endpoints: Composite endpoint, ALP not Stephen HARRISON (San Antonio, USA) | malization and itch |
| 13:25 | Q&A with audience | |
| 14:00 14:45 | R&D SESSION 1: The drug pipelines presented by Companies | |
| | Chairs: Raymond SCHINAZI (USA), Geoffrey DUSHEIKO (UK) | |
| 14:00 | GILEAD Gilead Commitment to Liver Diseases Christophe HEZODE (Medical Affairs, Gilead) | |
| 14:15 | BOSTON PHARMACEUTICALS BOS-580, a once-monthly FGF21 analogue, investigational treatment for MA Matthew BRYANT (VP of Medical Affairs, Boston Pharmaceuticals) | SH |
| 14:30 | GSK GSK Hepatology Pipeline Diogo FERRINHO (Global Medical Affairs Lead, GSK) | |
| 18:30 19:00 | SYMPOSIUM GILEAD Chronic viral hepatitis C & Delta | GILEAD |
| 19.00 | Chair: Maria BUTI (Barcelona, Spain) | |
| 18:30 | 10 years of all-oral therapies for HCV and tomorrow? Maria BUTI (Barcelona, Spain) | |
| 18:45 | Hepatitis Delta: current knowledge and management of patients Tarik ASSELAH (Paris, France) | |

End of the symposium

19:00

TUESDAY, MARCH 19TH

Partners' sessions program



CIS Auditoriun

| 12:45 | SYMPOSIUM NOVO NORDISK | |
|-------|------------------------|--|
| 12:45 | STMPUSIUM NUVU NURDISK | |

13:45 Preparing for multidisciplinary mash management: what is your role?



Chairs:

Objective: To discuss the barriers to and approaches for implementing effective multidisciplinary management of MASH in clinical practice

12:45 Welcome and introduction

12:55 Barrier 1: Early screening/evaluation

Cyrielle CAUSSY (Lyon, France), Jérôme BOURSIER (Angers, France)

13:10 Barrier 2: Timely referral

Cyrielle CAUSSY (Lyon, France), Jérôme BOURSIER (Angers, France)

13:25 Barrier 3: Optimising cardiometabolic risk management

Cyrielle CAUSSY (Lyon, France), Jérôme BOURSIER (Angers, France)

13:40 Summary and conclusion

Congress center, Room 1

12:45 WORKSHOP ROCHE

13:15 From randomized trials to real-world data (RWD): complementary approaches



Chairs: Marie LEQUOY, Pierre NAHON (France)

12:45 Illustration based on clinical cases

Marie LEQUOY (Paris, France)

12:55 How can RWD impact clinical practice?

Pierre NAHON (Bobigny, France)

13:10 Questions / Debates

14:00 R&D SESSION 2:

14:45 The drug pipelines presented by Companies

Chairs: Raymond SCHINAZI (USA), Geoffrey DUSHEIKO (UK)

14:00 NOVO NORDISK

Novo Nordisk's commitment in Liver Disease

Dmitry ESTULIN (Senior Medical Director, Novo Nordisk)

14:15 AKERO

Efruxifermin for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Vlad RATZIU (Hospital Pitié-Salpêtrière, Paris, France)

14:30 MADRIGAL PHARMACEUTICALS

Overview and Update on the MAESTRO Development Program

Peter RYDQVIST (European Medical Director, Madrigal Pharmaceuticals)

PARTNERS



SILVER PARTNERS





BRONZE PARTNERS -















PARTNERS





echosens